Clinicopathological characteristics of unicentric retroperitoneal Castleman’s disease: a study of 14 cases

Wang, Shuai; Chen, Shanwen; Xu, Jiangfeng; Cai, Song-Liang

doi:10.1186/s12957-015-0756-6

Cited by 19 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 1 summarizes published data and data from the ongoing ACCEL-ERATE natural history registry 32 from the CDCN and University of Pennsylvania. 12,19,[33][34][35][36][37][38][39][40][41][42][43][44][45] The consensus focused on 2 main topics: treatment of resectable UCD and treatment of unresectable UCD. Levels of evidence were modeled after National Comprehensive Cancer Network guidelines.…”

Section: Introductionmentioning

confidence: 99%

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

et al. 2020

View full text Add to dashboard Cite

Castleman disease (CD) includes a group of rare and heterogeneous disorders with characteristic lymph node histopathological abnormalities. CD can occur in a single lymph node station, which is referred to as unicentric CD (UCD). CD can also involve multicentric lymphadenopathy and inflammatory symptoms (multicentric CD [MCD]). MCD includes human herpesvirus-8 (HHV-8)–associated MCD, POEMS-associated MCD, and HHV-8−/idiopathic MCD (iMCD). The first-ever diagnostic and treatment guidelines were recently developed for iMCD by an international expert consortium convened by the Castleman Disease Collaborative Network (CDCN). The focus of this report is to establish similar guidelines for the management of UCD. To this purpose, an international working group of 42 experts from 10 countries was convened to establish consensus recommendations based on review of treatment in published cases of UCD, the CDCN ACCELERATE registry, and expert opinion. Complete surgical resection is often curative and is therefore the preferred first-line therapy, if possible. The management of unresectable UCD is more challenging. Existing evidence supports that asymptomatic unresectable UCD may be observed. The anti–interleukin-6 monoclonal antibody siltuximab should be considered for unresectable UCD patients with an inflammatory syndrome. Unresectable UCD that is symptomatic as a result of compression of vital neighboring structures may be rendered amenable to resection by medical therapy (eg, rituximab, steroids), radiotherapy, or embolization. Further research is needed in UCD patients with persisting constitutional symptoms despite complete excision and normal laboratory markers. We hope that these guidelines will improve outcomes in UCD and help treating physicians decide the best therapeutic approach for their patients.

show abstract

Section: Introductionmentioning

confidence: 99%

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…According to results of histopathology, CD could be subclassified into three types, hyaline-vascular, plasma-cell, and mixed types, and also could be subclassified into UCD and MCD on the basis of clinical features [3] . MCD may present as thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly [2] .…”

Section: Discussionmentioning

confidence: 99%

Clinical analysis of surgical treatment for retroperitoneal unicentric Castleman Disease: a single-centre experience for 10 years

Wang¹,

Dong²,

Wen³

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective Diagnosis of unicentric Castleman Disease (UCD) is not easy before the resection and obtainment of pathological result. We summarized 10-year experience of clinical management for retroperitoneal UCD in PUMCH. Methods A retrospective analysis of retroperitoneal UCD between December 1st, 2009 and December 31th, 2019 in PUMCH was carried out. Epidemiological data, imaging and laboratorial examinations, and histopathological results after resection were reviewed and analyzed. The long-term follow up was performed in these retroperitoneal UCD patients. Results 72 UCD patients with pathological diagnosis after resection were screened out. Among them 25 patients had retroperitoneal UCD. The average age of the 25 patients was 43.80±12.79, and 52.00% were male. No patients had systemic symptoms, and one patient got pre-operative treatment. The average size of masses was 5.59±2.86cm. The UCD sites included kidney, adrenal area, perinephric area, pancreas, peripancreatic area, area of descending part of duodenum, periaortic area or beside iliac artery, and others. The masses presented different degree of enhancement on CT scans and hypoecho or isoecho on ultrasound. Increased metabolism could be found on 18 F-FDG PET/CT. Some patients had positive results on somatostatin receptor imaging, but none had positive results on 131 I-MIBG. Some patients presented the elevated level of IL-6, 24h-urinary catecholamine and tumor markers. All the patients received complete resection of masses and 96.00% had hyaline-vascular type pathology except one patient (plasma cell-type). 92.00% patients received a long-term follow up with an average follow-up time of 35.48±33.90 months. No patients died or experienced relapse during follow up. Conclusions Differential diagnosis of retroperitoneal UCD may be difficult according to imaging and laboratorial examinations. Complete resection is the best treatment and could provide a final pathological diagnosis.

show abstract

“…Retroperitoneal localization of CD is not commonly seen and comprises only 11% of all the cases (10). The gold standard treatment for unicentric CD involves complete surgical resection of the lesion (3).…”

Section: Discussionmentioning

confidence: 99%

Retroperitoneal Castleman Disease Mimicking Paraganglioma in a Patient with Klinefelter Syndrome: A Case Report

Hepşen¹,

Özbek²,

Sencar³

et al. 2019

Turk J Endocrinol Metab

View full text Add to dashboard Cite

Clinicopathological characteristics of unicentric retroperitoneal Castleman’s disease: a study of 14 cases

Cited by 19 publications

References 13 publications

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease

Clinical analysis of surgical treatment for retroperitoneal unicentric Castleman Disease: a single-centre experience for 10 years

Retroperitoneal Castleman Disease Mimicking Paraganglioma in a Patient with Klinefelter Syndrome: A Case Report

Contact Info

Product

Resources

About